Drug therapy to kill myeloma cells is the mainstay of treatment for myeloma. Drug therapy can cause side effects, especially when chemotherapy is involved. Potent chemotherapy drugs must be toxic enough to kill cancerous cells. At the same time, they take aim at normal cells and cause side effects. Yet, not everyone experiences side effects and people react differently.
If you're experiencing myeloma symptoms, your doctor will first decide whether you could be a candidate for stem cell transplantation. For transplant candidates, drug treatment begins with a combination of induction agents that do not cause marrow damage.
Some patients may not want a stem cell transplant, and for other patients—such as certain older patients or patients with other medical problems—the potential risks of transplantation may outweigh the benefits. For patients who are not transplant candidates, treatment may begin with a combination drug therapy. Often, two or three drugs are used simultaneously. As many as six drugs are combined in some intensive treatment programs. You may be given the drugs as pills to swallow, by injection or through a catheter (a thin, flexible tube or intravenous line) surgically placed in a vein, normally in your upper chest.
Drug therapy has led to long-term remission in some patients and a temporary remission or significant slowing of the disease in other patients. As newer, more effective drugs become available, longer remission periods are becoming more common, and some patients who have been treated with these drugs may be functionally cured of their disease.
Drugs Used for Myeloma Treatment
Drugs regularly used to treat myeloma include:
- Thalidomide (Thalomid®)
- Lenalidomide (Revlimid®)
- Bortezomib (Velcade®)
- Velcade® and liposomal doxorubicin (Doxil®)
- Carfilzomib (Kyprolis™)
- Pomalidomide (Pomalyst®)
- Panobinostat (Farydak®)
For information about these drugs, visit Drug Listings.
For information about other drugs and drug combinations used for myeloma treatment, access the free booklet, Myeloma.